aTyr Pharma (STU:471A) Cyclically Adjusted Book per Share: €11.63 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:471A aTyr Pharma Inc STU:471A
27 GF Score
Price €0.42
GF Value €0.38
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is aTyr Pharma Cyclically Adjusted Book per Share?

aTyr Pharma STU:471A -4.59% 27 Cyclically Adjusted Book per Share is €11.63 as of Mar. 2026. GuruFocus rates STU:471A with a GF Score™ of 27/100 and a GF Value™ of €0.38 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

aTyr Pharma's adjusted book value per share for the three months ended in Mar. 2026 was €0.511. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €11.63 for the trailing ten years ended in Mar. 2026.

During the past 12 months, aTyr Pharma's average Cyclically Adjusted Book Growth Rate was -39.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-27), aTyr Pharma's current stock price is €0.416. aTyr Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €11.63. aTyr Pharma's Cyclically Adjusted PB Ratio of today is 0.04.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of aTyr Pharma was 0.29. The lowest was 0.03. And the median was 0.09.


aTyr Pharma  (STU:471A) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

aTyr Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.416/11.63
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of aTyr Pharma was 0.29. The lowest was 0.03. And the median was 0.09.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


aTyr Pharma Cyclically Adjusted Book per Share Related Terms


aTyr Pharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for aTyr Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

aTyr Pharma Cyclically Adjusted Book per Share Chart

aTyr Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 17.66 19.83 12.16

aTyr Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.75 17.38 18.56 12.16 11.63

STU:471A vs IBO, BYSI, MCRB: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, aTyr Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


aTyr Pharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, aTyr Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's Cyclically Adjusted PB Ratio falls into.


STU:471A
27GF Score
aTyr Pharma Inc STU:471A
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

aTyr Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, aTyr Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.511/330.2130*330.2130
=0.511

Current CPI (Mar. 2026) = 330.2130.

aTyr Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201606 45.482 241.018 62.314
201609 38.916 241.428 53.227
201612 35.103 241.432 48.011
201703 27.905 243.801 37.796
201706 20.921 244.955 28.203
201709 28.567 246.819 38.219
201712 25.486 246.524 34.138
201803 20.740 249.554 27.443
201806 18.209 251.989 23.862
201809 15.663 252.439 20.489
201812 13.530 251.233 17.783
201903 10.008 254.202 13.001
201906 7.575 256.143 9.765
201909 6.240 256.759 8.025
201912 4.899 256.974 6.295
202003 4.077 258.115 5.216
202006 3.416 257.797 4.376
202009 2.733 260.280 3.467
202012 2.361 260.474 2.993
202103 2.608 264.877 3.251
202106 2.086 271.696 2.535
202109 3.597 274.310 4.330
202112 3.480 278.802 4.122
202203 3.189 287.504 3.663
202206 2.914 296.311 3.247
202209 2.687 296.808 2.989
202212 2.287 296.797 2.544
202303 1.924 301.836 2.105
202306 1.719 305.109 1.860
202309 1.574 307.789 1.689
202312 1.314 306.746 1.415
202403 1.137 312.332 1.202
202406 1.000 314.175 1.051
202409 0.776 315.301 0.813
202412 0.796 315.605 0.833
202503 0.780 319.799 0.805
202506 0.699 322.561 0.716
202509 0.698 324.800 0.710
202512 0.588 324.054 0.599
202603 0.511 330.213 0.511

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €11.63 mean?
aTyr Pharma (STU:471A) has a Cyclically Adjusted Book per Share of €11.63 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on aTyr Pharma and its competitors.
Is aTyr Pharma's Cyclically Adjusted Book per Share too high?
aTyr Pharma's current Cyclically Adjusted Book per Share is €11.63. Overall, aTyr Pharma has a GF Score™ of 27/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's Cyclically Adjusted Book per Share compare to IBO and BYSI?
aTyr Pharma's Cyclically Adjusted Book per Share of €11.63 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on aTyr Pharma and its competitors. aTyr Pharma's current Cyclically Adjusted Book per Share is €11.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (STU:471A) is currently considered Fairly Valued. The stock's GF Value™ is €0.38, compared to a current price of €0.42 — trading 9.5% above its estimated fair value. The current Cyclically Adjusted Book per Share is €11.63. aTyr Pharma's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For aTyr Pharma (STU:471A), the current Cyclically Adjusted Book per Share is €11.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is aTyr Pharma (STU:471A) Overvalued in 2026?

Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued. The current stock price of €0.42 is trading 9.5% above its estimated GF Value™ of €0.38. GuruFocus considers aTyr Pharma to be Fairly Valued.

Key valuation signals for STU:471A:

  • Cyclically Adjusted Book per Share: €11.63
  • GF Value™: €0.38 vs. price of €0.42 (9.5% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the STU:471A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


aTyr Pharma Business Description

Other Exchanges ATYR:USA
Address 10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
27GF Score

Get the complete analysis for STU:471A

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.42
Price
€0.38
GF Value